Diseasemodifying drugs - Biotech, Pharma and Life Science Channel

17:47 EDT 28th July 2015 | BioPortfolio

PubMed Articles [4658 Associated PubMed Articles listed on BioPortfolio]

Maximum flow approach to prioritize potential drug targets of Mycobacterium tuberculosis H37Rv from protein-protein interaction network.

In spite of the implementations of several strategies, tuberculosis (TB) is overwhelmingly a serious global public health problem causing millions of infections and deaths every year. This is mainly d...

The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia.

Cyclooxygenase (COX)-2 inhibitors including celecoxib are as effective as non-selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) in the treatment of osteoarthritis (OA) and have less gastroin...

A modified emulsion gelation technique to improve buoyancy of hydrogel tablets for floating drug delivery systems.

The use of buoyant or floating hydrogel tablets is of particular interest in the sustained release of drugs to the stomach. They have an ability to slow the release rates of drugs by prolonging their ...

Alternative approach of cell encapsulation by Volvox spheres.

Volvox sphere is a bio-mimicking concept of a biomaterial structure design able to encapsulate chemicals, drugs and/or cells. The aim of this study was to prepare Volvox spheres encapsulating AML12 li...

Water soluble biocompatible vesicles based on polysaccharides and oligosaccharides inclusion complexes for carotenoid delivery.

Since carotenoids are highly hydrophobic, air- and light-sensitive hydrocarbon compounds, developing methods for increasing their bioavailability and stability towards irradiation and reactive oxygen ...

Carvacrol inhibits proliferation and induces apoptosis in human colon cancer cells.

Colon cancer is one of the most common malignancies worldwide and has a high mortality rate. Carvacrol is a major component of oregano and thyme essential oils and shows antitumor properties. Here, we...

Rapid analysis of synthetic cannabinoids using a miniature mass spectrometer with ambient ionization capability.

Synthetic cannabinoids are an emerging class of drugs of abuse and are of a great concern for transport control and usage regulation. In this study, we have developed rapid analytical methods using a ...

A categorical review on electroanalytical determination of non-narcotic over-the-counter abused antitussive drugs.

Dextromethorphan (DXM) and diphenhydramine (DPH) are two commonly used over-the-counter non-narcotic antitussive drugs. Recent reports reveal the widespread abuse of DXM and DPH due to their euphoric ...

A comprehensive study of the enantioseparation of chiral drugs by cyclodextrin using capillary electrophoresis combined with theoretical approaches.

Four chiral drugs were enantioseparated by native beta-cyclodextrin (β-CD) and negatively charged carboxymethyl-beta-cyclodextrin (CM-β-CD) using capillary electrophoresis coupled with electrochemil...

Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?

Non-Hodgkin lymphoma is a diverse group of lymphocyte-derived neoplasms. Although a heterogeneous group of malignancies, it has become apparent that epigenetic alterations, such as disturbances of DNA...

News Articles [4997 Associated News Articles listed on BioPortfolio]

UPDATE 1-Gilead Q2 profit beats Wall Street, 2015 sales outlook raised

July 28 (Reuters) - Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates.

AHF Says Jeffrey Sachs’ “Gilead’s Greed That Kills” Commentary is “Right on the Money”

On World Hepatitis Day, with 150 million people worldwide living with Hepatitis C, AHF lauds Dr. Jeffrey Sachs for calling out Gilead Sciences on its greed, when he wrote, “Gile...

Gilead 2nd-quarter profit increases 32 pct, 2015 outlook raised

July 28 (Reuters) - Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates.

Training in addiction medicine should be standardised and scaled up

Substance use disorders represent a substantial social and public health burden. An estimated 149 million to 271 million people use illicit drugs worldwide,1 and the related physical and...

Global majors oppose appointment of Rostec sole supplier of anti-HIV and TB drugs in Russia

Rostec, a Russian state corporation which specializes in development, production and export of hi-tech…

Glitazone drugs could play a role in prevention of Parkinson’s disease

Patients who take glitazone drugs to manage their diabetes may have some protection from developing Parkinson’s disease, suggests new research.

FDA Says Doctors Should Consider Limiting MRIs As Agency Investigates Risks To Brain

The Food and Drug Administration issued the safety announcement as it looks into whether contrast-imaging drugs that contain the heavy metal gadolinium leave brain deposits after repeated MRIs. Meanwh...

Study: Firms 'Underinvest' in Long-Term Cancer Research

Pharmaceutical firms “underinvest” in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published stu...

Innovative New Consortium Formed to Develop, Study Early Stage Drugs

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some...

Matinas BioPharma moves focus to anti-infectives

After moving a novel omega-3 program through a successful Phase 2 program, Matinas BioPharma Holdings (OTCQB:MTNB) is now advancing two anti-infective drug candidates in the war against drug resistanc...

Events [0 Results]

None

Companies [247 Associated Companies listed on BioPortfolio]

Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the fun...

Hanmi Pharmaceutical co., Ltd.

Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting ...

Center for Infectious Disease Research

Center for Infectious Disease Research is the largest independent, non-profit organization in the U.S. focused solely on infectious disease research. Our mission is to make transf...

Tanner Pharma Group

For over 15 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners around the world. Leading pharmaceutical and biotech companies partn...

Thetis Pharmaceuticals, LLC

Thetis Pharmaceuticals is a privately held biopharmaceutical company applying its expertise in amino-lipid chemistry to discover and develop innovative drugs for the treatment of ...

Iris Pharma

Iris Pharma is a Contract Research Organizations (CROs) providing drug development services to Research Institutes, Pharmaceutical or Biotechnology Industries, to support the preclinical development a...

Proteo Biotech AG

The company researches, develops and markets compounds for biological and medical research as well as for use as pharmaceuticals. The main focus is on anti-inflammatory drugs, in ...

MedDay

MedDay is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executi...

Cerecor Inc.

Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving t...

MediVector, Inc.

MediVector, Inc. is a Boston-based drug development company specializing in decreasing the time and cost of bringing drugs to market. The company complements its team’s clini...

Clinical Trials [256 Associated Clinical Trials listed on BioPortfolio]

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may s...

An Observational Study in Clinical Practice Management of Patients With Biological Drugs in Monotherapy

This observational multicenter study will evaluate the management of disease and safety in clinical practice in patients with moderate to severe rheumatoid arthritis receiving any biologic...

Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)

This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.

Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the ...

A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)

This purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following bunionectomy surgery.

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the...

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.

Vytorin Reexamination Study (0653A-174)

This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical us...

Cozaar XQ Re-examination Study (MK-0954-349)

This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Law and its Enforcement Regulation; its aim is to reconfirm the clinical use...

Videos

None available.

Medical and Biotech [MESH] Definitions

Drugs used by veterinarians in the treatment of animal diseases. The veterinarian's pharmacological armamentarium is the counterpart of drugs treating human diseases, with dosage and administration adjusted to the size, weight, disease, and idiosyncrasies of the species. In the United States most drugs are subject to federal regulations with special reference to the safety of drugs and residues in edible animal products.

Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.

The use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication. Since in the United States most drugs are dispensed as single-agent formulations, polypharmacy, though using many drugs administered to the same patient, must be differentiated from DRUG COMBINATIONS, single preparations containing two or more drugs as a fixed dose, and from DRUG THERAPY, COMBINATION, two or more drugs administered separately for a combined effect. (From Segen, Dictionary of Modern Medicine, 1992)

Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here.

Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.


Advertisement
 
Advertisement
 
review and buy Diseasemodifying drugs market research data and corporate reports here

Channels Quicklinks